Spectrum Academy
Keep moving forward
Take advantage of the further education and training opportunities
offered by the Dr. Erkens Consulting Group
Spectrum-Academy
The range of services offered by the Dr. Erkens Consulting Group includes the conception and carrying out of various information and training events as well as education and training programmes. We have bundled this as a further business line of the Dr. Erkens Consulting Group, under the umbrella of the Spectrum Academy.
Subject Areas
The main topics of the Spectrum Academy’s further education and training programme are essentially oriented towards the business areas of the Dr. Erkens Consulting Group.
Analysis | Market Research
Strategy | Implementation
Marketing | Sales
Communication | Education
Organisation | Processes
Innovation | Leadership
Formats
The constantly evolving event portfolio includes:
- Individually designed in-house events at our clients’ premises
- Centrally organized practice-oriented seminars and interactive workshops
- Online events and training courses
Target group
Our offer is specifically aimed at professionals from the healthcare, medical, pharmaceutical, medtech and life sciences industries. It is rounded off by special training courses for employees of companies from the above-mentioned sectors and start-ups, and medical events for patients.
Partners
The Spectrum Academy is supported and co-sponsored by longstanding and trustworthy partner companies such as the be-sign.net agency (which specialises in print and web design) and Aurum Research (which examines the international healthcare market).
Anschrift
Dr. Erkens Consulting Group
Industriestraße 13
64380 Roßdorf
Tel: +49 (0)6154 – 6967 – 944
Mobil +49 (0)179 – 2 41 10 29
info@dr-erkens-consulting.de
Social
News
Dr. Erkens Consulting Group
- Neue Website der Dr. Erkens Consulting Group geht online
Source: Dr. Erkens Consulting Group 09/2020 - Integrierte Pharma-News auf der Dr. Erkens Consulting Group Website
Source: Dr. Erkens Consulting Group 09/2020
Pharma Letter
- BRIEF—J&J seeks indication extension of Akeega in prostate cancer
- EU strategy aims to put life sciences back on the map
- BRIEF—Boehringer selects third drug from collab to advance into IND-enabling studies
- ABPI sees faults in NHS 10-Year Health Plan
- Ingenza appoints Nick Challoner as CEO to lead next growth phase
Pharma Relations
Pharma Times
- First German haemophilia B patient receives gene therapy HEMGENIX
- Neumifil shows promise in treating influenza with positive phase 2 dat
- Moderna flu vaccine shows superior results in phase 3 study
- UCB reports success in phase 3 study of fenfluramine for CDD
- Cidara and hVIVO report positive results in flu prevention study
Our Place on Earth
Kartenbild: OpenStreetMap, ODbL 1.0